Short Bowel Syndrome Market

Short Bowel Syndrome Market was valued US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a XX% CAGR of around XX% during a forecast period.

Short Bowel Syndrome Market

Short bowel syndrome affect the functional ability of intestine. Patients suffering from short bowel syndrome have a decreased capability to absorb trace elements, vitamins, fats, fluids, minerals and carbohydrates and can experience weight loss, malnutrition, diarrhea and dehydration. Currently, there is no treatment for short bowel syndrome but the treatment is directed towards symptoms. In a rare cases, short bowel syndrome is life-threatening but usually, the disease can treated through effective medication. Treatment mostly comprises nutrition & diet management, medication and surgery. In treatment, Teduglutide was first permitted by the FDA for short bowel syndrome disorder and other treatments contain antidiarrheal, proton pump, inhibitors histamine blockers, and growth hormones.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The scope of the report includes a detailed study of global and regional markets for Short Bowel Syndrome with the reasons given for variants in the growth of the industry in certain regions.

Growing awareness and convenience of epidemiological data lead to the improved controlling of short bowel disease. Additionally, rapid developments in the field of healthcare have raised awareness about short bowel syndrome and thus, creates opportunities in future. Similarly, non-profit organizations are encouraging research & development about short bowel syndrome in joint scientific research among the public and private sector. In relationship with non-profit organizations, state governments offer special incentives to manufacturers for the improvement of short bowel syndrome drugs. The expansion of short bowel syndrome drugs is at an emerging stage, which generates more opportunities for global players. Public-private partnerships are inspiring pharmaceutical companies to improve new orphan drugs for short bowel syndrome. Few countries have executed a combination of legislations, regulations, and policies indorsing drug development for short bowel syndrome. These are the potential drivers for the growth of the short bowel syndrome market. Instead of this, a lack of sanctioned treatment options may lead to the down regulate the growth of short bowel syndrome market.

The report on Short Bowel Syndrome market covers segments such as by Drug Type, Distribution Channel and Region. The Drug Type segment includes Glucagon-like Peptide, Anti-Diarrheals, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, and Others. Among the Drug Type, Glucagon-like Peptide is accounted for the largest XX% share in the Short Bowel Syndrome market. Currently, Glucagon-Like Peptide is leading the market because of its wide presence in the U.S. and Europe. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Specialty Pharmacies, and Others. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest XX% market share in the Short Bowel Syndrome market. The Hospital Pharmacies from Distribution Channel segment is anticipated to have a reasonable growth during the forecasted period.

Based on regional segment, the Short Bowel Syndrome market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market during forecasted period. The rising prescriptions for Glucagon-like Peptide treatment in the U.S. is anticipated to driver the growth for the North America short bowel syndrome market. Additionally, the fact that glutamine and growth hormone are only permitted in the U.S. for treating SBS is anticipated to keep North America in the lead. The increasing awareness about short bowel syndrome amongst consumers and outstanding reimbursement strategies are anticipated to fuel the regional market during forecast period.

Key players operating in the Short Bowel Syndrome market are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, Zealand Pharma A/S, Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, and Johnson & Johnson. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Short Bowel Syndrome market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Short Bowel Syndrome market.

Scope of the Short Bowel Syndrome Market

Short Bowel Syndrome Market, By Drug Type

• Glucagon-like Peptide
  
• Anti-Diarrheals
  
• Histamine Blockers
  
• Proton Pump Inhibitors
  
• Growth Hormone
  
• Others
  

Short Bowel Syndrome Market, By Distribution Channel

• Hospital Pharmacies
  
• Specialty Pharmacies
  
• Others.
  

Short Bowel Syndrome Market, By Region

• North America
  
• Europe
  
• Asia Pacific
  
• Middle East & Africa
  
• South America
  

Key players operating in the Global Short Bowel Syndrome Market

• Ardelyx, Inc.
  
• Emmaus Life Sciences, Inc.
  
• GLyPharma Therapeutic, Inc.
  
• Merck KGaA
  
• Naia Pharmaceuticals, Inc.
  
• Nutrinia Ltd.
  
• OxThera, Sancilio & Company, Inc.
  
• Shire plc.
  
• Zealand Pharma A/S.
  
• Swedish Orphan Biovitrum AB.
  
• Novartis AG
  
• Pfizer Inc.
  
• Teva Pharmaceutical Industries Ltd.
  
• Mylan N.V.
  
• AstraZeneca Plc.
  
• Johnson & Johnson
  

More Information:

https://www.maximizemarketresearch.com/market-report/short-bowel-syndrome-market/37257/Report Is Submitted By : Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

This Report Is Submitted By : Maximize Market Research Company

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908 8989132284

 

[Dhruv Bindhani]

This report provides an overview of the Short Bowel Syndrome (SBS) Market, detailing its current valuation, projected growth, key characteristics of the condition, existing treatments, and market drivers.

---

Short Bowel Syndrome Market: Overview and Outlook​

Short Bowel Syndrome (SBS) is a condition impairing the intestine's functional ability, leading to malabsorption of essential nutrients and symptoms like weight loss, malnutrition, diarrhea, and dehydration. While potentially life-threatening in rare cases, it's generally manageable through medication, nutrition/diet management, and surgery. Teduglutide (a Glucagon-like Peptide) is noted as the first FDA-approved treatment, with other medications including antidiarrheals, proton pump inhibitors, histamine blockers, and growth hormones.

Market Dynamics and Growth Drivers​

The market, valued at US$ XX Bn in 2019 and projected to reach US$ XX Bn by 2027 with a XX% CAGR, is driven by several factors. Increasing awareness and the availability of epidemiological data are improving SBS control. Rapid advancements in healthcare and efforts by non-profit organizations are fostering R&D, often through public-private partnerships. State governments are also providing incentives for drug manufacturers, encouraging the development of new orphan drugs for this emerging market.

However, a significant challenge remains the lack of sanctioned treatment options, which could hinder market growth. The report acknowledges the revenue impact of the COVID-19 pandemic on market players.

Market Segmentation and Dominance​

The report segments the market by Drug Type, Distribution Channel, and Region:

• Drug Type: Glucagon-like Peptide (Teduglutide) currently holds the largest market share (XX%), primarily due to its established presence in the U.S. and Europe. Other drug types include Anti-Diarrheals, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, and Others.
• Distribution Channel: Hospital Pharmacies account for the largest market share (XX%), with Specialty Pharmacies and Others making up the rest. Hospital Pharmacies are expected to show reasonable growth.

Geographically, North America is projected to dominate the market. This is attributed to the increasing prescription of Glucagon-like Peptide treatments in the U.S. and the fact that glutamine and growth hormone therapies for SBS are only permitted in the U.S. Growing consumer awareness and favorable reimbursement strategies further contribute to North America's leading position.

Key Players and Future Outlook​

Leading companies in the SBS market, including Shire plc (now Takeda), Novartis AG, Pfizer Inc., and Johnson & Johnson, are actively investing in R&D and funding clinical trials to strengthen their product pipelines. With anticipated increases in detection rates and market perception, along with new product approvals, the market is expected to experience continued growth during the forecast period.

The report aims to provide a comprehensive assessment, including competitive analysis, market segmentation, and strategic insights (PEST, PORTER's, and SWOT analyses) to guide stakeholders.